Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 598 | 532 | 146 | 544 | 458 |
| Gross Profit | 598 | 532 | 146 | 544 | 458 |
| Operating Expenses | 49,572 | 24,056 | 16,623 | 17,371 | 16,961 |
| Operating Income | -48,974 | -23,524 | -16,477 | -16,827 | -16,503 |
| Other Income | 855 | 1,086 | 1,338 | 1,192 | 897 |
| Pre-tax Income | -48,119 | -22,438 | -15,139 | -15,635 | -15,606 |
| Income Tax | 12 | 14 | 17 | 16 | 12 |
| Net Income Continuous | -48,131 | -22,452 | -15,156 | -15,651 | -15,618 |
| Net Income | $-48,131 | $-22,452 | $-15,156 | $-15,651 | $-15,618 |
| EPS Basic Total Ops | -36.76 | -17.50 | -9.50 | -13.50 | -18.00 |
| EPS Basic Continuous Ops | -36.77 | -17.54 | -9.24 | -13.74 | -17.88 |
| EPS Diluted Total Ops | -36.76 | -17.50 | -9.50 | -13.50 | -18.00 |
| EPS Diluted Continuous Ops | -36.77 | -17.54 | -9.24 | -13.74 | -17.88 |
| EPS Diluted Before Non-Recurring Items | -14.50 | -17.50 | -11.00 | N/A | N/A |
| EBITDA(a) | $-49,504 | $-24,321 | $-17,480 | $-17,951 | $-17,152 |